|
|
Article: Axonyx Reports Expected' Miss With Phenserine In AD.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Axonyx Inc. reported disappointing, though not unexpected, results from its final two Phase III trials of Phenserine in mild to moderate Alzheimer's disease patients.
The New York-based company said top-line data failed to show statistical significance over placebo, as measured by standard cognition scales. Those results confirmed findings reported in February from the first Phase III study of Phenserine, a selective acetylcholinesterase inhibitor, in which the drug failed to meet its cognition endpoint of improved memory in 375 patients. (See BioWorld Today, March 15, 2005.)
"We kind of knew we would probably not achieve ...